{"id":"https://openalex.org/W4401280680","doi":null,"title":"Libtayo\u00ae (Cemiplimab-rwlc) Injection for Intravenous Use.","display_name":"Libtayo\u00ae (Cemiplimab-rwlc) Injection for Intravenous Use.","publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W4401280680","pmid":"https://pubmed.ncbi.nlm.nih.gov/39090000"},"language":"en","primary_location":{"id":"pmid:39090000","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39090000","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100603158","display_name":"Aditya Kumar Gupta","orcid":"https://orcid.org/0000-0002-8664-7723","observed_orcids":["https://orcid.org/0000-0002-8664-7723"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Aditya K Gupta","raw_affiliation_strings":["Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","Mediprobe Research Inc., London, Ontario, Canada; agupta@mediproberesearch.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I185261750"]},{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada; agupta@mediproberesearch.com","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073064001","display_name":"Avantika Mann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Avantika Mann","raw_affiliation_strings":["Mediprobe Research Inc., London, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077394930","display_name":"Kimberly Dawn Vincent","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly Vincent","raw_affiliation_strings":["Private Practice Sevierville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private Practice Sevierville, TN","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033724363","display_name":"William Abramovits","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123534392","display_name":"University of North Texas","ror":"https://ror.org/00v97ad02","country_code":"US","type":"education","lineage":["https://openalex.org/I123534392"]},{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]},{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Abramovits","raw_affiliation_strings":["University of Texas at Southwestern Medical School, Dallas, TX","Baylor Scott & White University Hospital, Dallas, TX","The University of North Texas Dermatology Residency Program, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas at Southwestern Medical School, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]},{"raw_affiliation_string":"Baylor Scott & White University Hospital, Dallas, TX","institution_ids":["https://openalex.org/I4210160418"]},{"raw_affiliation_string":"The University of North Texas Dermatology Residency Program, Dallas, TX","institution_ids":["https://openalex.org/I123534392"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3782,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.59274263,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"22","issue":"2","first_page":"138","last_page":"143"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12009","display_name":"Hedgehog Signaling Pathway Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.7509999871253967},{"id":"https://openalex.org/keywords/locally-advanced-basal-cell-carcinoma","display_name":"locally advanced basal cell carcinoma","score":0.7670000195503235},{"id":"https://openalex.org/keywords/metastatic-basal-cell-carcinoma","display_name":"metastatic basal cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.9589999914169312},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6869999766349792},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.953000009059906},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.8669999837875366},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6610000133514404},{"id":"https://openalex.org/keywords/safety-profile","display_name":"safety profile","score":0.5320000052452087}],"concepts":[{"id":"https://openalex.org/C127313418","wikidata":"https://www.wikidata.org/wiki/Q1069","display_name":"Geology","level":0,"score":0.3982953727245331}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002280","descriptor_name":"Basal Cell Carcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:39090000","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39090000","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4214599231","https://openalex.org/W4237433135","https://openalex.org/W2973309783","https://openalex.org/W6920709102","https://openalex.org/W4213021979","https://openalex.org/W3160231856","https://openalex.org/W4392710900","https://openalex.org/W3021674061","https://openalex.org/W4205836731","https://openalex.org/W2907748842"],"abstract_inverted_index":{"(cemiplimab-rwlc)":[0],"injection":[1],"for":[2,16,45,93,230],"intravenous":[3],"use":[4],"was":[5,40,91,115,140,158,193,220],"recently":[6],"approved":[7,41],"by":[8,42,77],"the":[9,31,37,43,46,65,79,94,125,147,154,181,197,203,210],"US":[10],"Food":[11],"and":[12,23,55,104,130,143,149,172,206,217,238],"Drug":[13],"Administration":[14],"(FDA)":[15],"locally":[17,56],"advanced":[18,32,57,66,97,105,234],"basal":[19,25],"cell":[20,26,52,60],"carcinoma":[21,27,53,61],"(laBCC)":[22],"metastatic":[24,49],"(mBCC),":[28],"both":[29,63,128],"being":[30,64],"stages":[33,67,98,106,235],"of":[34,48,68,96,99,107,236],"BCC.":[35],"In":[36,83,124,153],"past,":[38],"it":[39],"FDA":[44],"treatment":[47,95],"cutaneous":[50,58],"squamous":[51,59],"(mCSCC)":[54],"(laCSCC),":[62],"CSCC.":[69],"Cemiplimab":[70],"is":[71,240],"a":[72],"monoclonal":[73],"antibody":[74],"that":[75],"works":[76],"blocking":[78],"programmed":[80],"death-1":[81],"pathway.":[82],"two":[84,161],"open-label,":[85],"single-arm,":[86],"phase":[87],"2":[88,178,190],"studies,":[89],"cemiplimab":[90,133,165,176,186,231],"investigated":[92],"BCC":[100,237],"(study":[101,109],"1620,":[102,127],"NCT03132636)":[103],"CSCC":[108,239],"1540,":[110],"NCT02760498).":[111],"The":[112,227],"primary":[113],"endpoint":[114],"objec-tive":[116],"response":[117],"rate":[118],"(ORR)":[119],"per":[120],"independent":[121],"central":[122],"review.":[123],"study":[126,155],"mBCC":[129,148],"laBCC":[131,150],"received":[132,185],"350":[134,166,241],"mg":[135,167,242],"every":[136,168,177,189,243],"3":[137,169,187,244],"weeks.":[138,191],"ORR":[139,192],"21%":[141],"(6/28)":[142],"31%":[144],"(26/84)":[145],"in":[146,196,202,209,222],"groups,":[151],"respectively.":[152],"1520,":[156],"mCSCC":[157],"divided":[159],"into":[160],"groups:":[162],"one":[163],"receiving":[164,174],"weeks":[170,179,245],"(Q3W)":[171],"another":[173],"3-mg/kg":[175],"(Q2W);":[180],"third":[182],"group,":[183,199,205],"laCSCC,":[184],"mg/kg":[188],"41%":[194],"(23/56)":[195],"Q3W":[198],"49%":[200],"(29/59)":[201],"Q2W":[204],"44%":[207],"(34/78)":[208],"laCSCC":[211],"group.":[212],"An":[213],"acceptable":[214],"safety":[215],"profile":[216],"antitumor":[218],"activity":[219],"discovered":[221],"patients":[223],"treated":[224],"with":[225],"cemiplimab.":[226],"recommended":[228],"dosage":[229],"to":[232],"treat":[233],"administered":[246],"intravenously":[247],"over":[248],"30":[249],"min.":[250]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2024-08-03T00:00:00"}